Literature DB >> 25201979

Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output.

Gloria Reyes1, Matt Niederst2, Ksenya Cohen-Katsenelson1, Joshua D Stender3, Maya T Kunkel1, Muhan Chen4, John Brognard1, Emma Sierecki1, Tianyan Gao5, Dawid G Nowak3, Lloyd C Trotman4, Christopher K Glass3, Alexandra C Newton6.   

Abstract

Growth factor receptor levels are aberrantly high in diverse cancers, driving the proliferation and survival of tumor cells. Understanding the molecular basis for this aberrant elevation has profound clinical implications. Here we show that the pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP) suppresses receptor tyrosine kinase (RTK) signaling output by a previously unidentified epigenetic mechanism unrelated to its previously described function as the hydrophobic motif phosphatase for the protein kinase AKT, protein kinase C, and S6 kinase. Specifically, we show that nuclear-localized PHLPP suppresses histone phosphorylation and acetylation, in turn suppressing the transcription of diverse growth factor receptors, including the EGF receptor. These data uncover a much broader role for PHLPP in regulation of growth factor signaling beyond its direct inactivation of AKT: By suppressing RTK levels, PHLPP dampens the downstream signaling output of two major oncogenic pathways, the PI3 kinase/AKT and the Rat sarcoma (RAS)/ERK pathways. Our data are consistent with a model in which PHLPP modifies the histone code to control the transcription of RTKs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25201979      PMCID: PMC4183331          DOI: 10.1073/pnas.1404221111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells.

Authors:  A Y Ting; K H Kain; R L Klemke; R Y Tsien
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation.

Authors:  Claudia Nitsche; Mouad Edderkaoui; Ryan M Moore; Guido Eibl; Noriyuki Kasahara; Janet Treger; Paul J Grippo; Julia Mayerle; Markus M Lerch; Anna S Gukovskaya
Journal:  Gastroenterology       Date:  2011-10-29       Impact factor: 22.682

4.  Pharmacological inhibition of pleckstrin homology domain leucine-rich repeat protein phosphatase is neuroprotective: differential effects on astrocytes.

Authors:  Travis C Jackson; Jonathan D Verrier; Tomas Drabek; Keri Janesko-Feldman; Delbert G Gillespie; Thomas Uray; Cameron Dezfulian; Robert S Clark; Hülya Bayir; Edwin K Jackson; Patrick M Kochanek
Journal:  J Pharmacol Exp Ther       Date:  2013-09-10       Impact factor: 4.030

5.  PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth.

Authors:  Jianyu Liu; Payton D Stevens; Xin Li; Micheal D Schmidt; Tianyan Gao
Journal:  Mol Cell Biol       Date:  2011-10-10       Impact factor: 4.272

6.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.

Authors:  Tianyan Gao; Frank Furnari; Alexandra C Newton
Journal:  Mol Cell       Date:  2005-04-01       Impact factor: 17.970

7.  Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors.

Authors:  L C Mahadevan; A C Willis; M J Barratt
Journal:  Cell       Date:  1991-05-31       Impact factor: 41.582

Review 8.  Hyperactive Ras in developmental disorders and cancer.

Authors:  Suzanne Schubbert; Kevin Shannon; Gideon Bollag
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

9.  Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C.

Authors:  John Brognard; Matthew Niederst; Gloria Reyes; Noel Warfel; Alexandra C Newton
Journal:  J Biol Chem       Date:  2009-03-26       Impact factor: 5.157

10.  Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer.

Authors:  Kang Su Cho; Joong Shik Lee; Nam Hoon Cho; Kyeongmee Park; Won Sik Ham; Young Deuk Choi
Journal:  Prostate       Date:  2008-06-01       Impact factor: 4.104

View more
  14 in total

1.  Deficiency in the phosphatase PHLPP1 suppresses osteoclast-mediated bone resorption and enhances bone formation in mice.

Authors:  Anna M Mattson; Dana L Begun; David H H Molstad; Margaret A Meyer; Merry Jo Oursler; Jennifer J Westendorf; Elizabeth W Bradley
Journal:  J Biol Chem       Date:  2019-06-12       Impact factor: 5.157

2.  Phlpp inhibitors block pain and cartilage degradation associated with osteoarthritis.

Authors:  Soyun M Hwang; Marina Feigenson; Dana L Begun; Lomeli Carpio Shull; Kirsty L Culley; Miguel Otero; Mary B Goldring; Lauren E Ta; Sanjeev Kakar; Elizabeth W Bradley; Jennifer J Westendorf
Journal:  J Orthop Res       Date:  2017-11-28       Impact factor: 3.494

Review 3.  PHLPPing the balance: restoration of protein kinase C in cancer.

Authors:  Hannah Tovell; Alexandra C Newton
Journal:  Biochem J       Date:  2021-01-29       Impact factor: 3.857

Review 4.  PHLPPing through history: a decade in the life of PHLPP phosphatases.

Authors:  Agnieszka T Grzechnik; Alexandra C Newton
Journal:  Biochem Soc Trans       Date:  2016-12-15       Impact factor: 5.407

Review 5.  PHLPP Signaling in Immune Cells.

Authors:  Gema Lordén; Avery J Lam; Megan K Levings; Alexandra C Newton
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

6.  Pleckstrin homology (PH) domain and Leucine Rich Repeat Phosphatase 1 (Phlpp1) Suppresses Parathyroid Hormone Receptor 1 (Pth1r) Expression and Signaling During Bone Growth.

Authors:  Samantha R Weaver; Earnest L Taylor; Elizabeth L Zars; Katherine M Arnold; Elizabeth W Bradley; Jennifer J Westendorf
Journal:  J Bone Miner Res       Date:  2021-02-08       Impact factor: 6.741

7.  High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma.

Authors:  Youyou Xie; Dongqing Lv; Wei Wang; Minhua Ye; Xiaofeng Chen; Haihua Yang
Journal:  Oncotarget       Date:  2017-08-01

8.  PHLPP1 counter-regulates STAT1-mediated inflammatory signaling.

Authors:  Ksenya Cohen Katsenelson; Joshua D Stender; Agnieszka T Kawashima; Gema Lordén; Satoshi Uchiyama; Victor Nizet; Christopher K Glass; Alexandra C Newton
Journal:  Elife       Date:  2019-08-13       Impact factor: 8.140

Review 9.  On the PHLPPside: Emerging roles of PHLPP phosphatases in the heart.

Authors:  Kellie A Lemoine; Julianna M Fassas; Shirag H Ohannesian; Nicole H Purcell
Journal:  Cell Signal       Date:  2021-07-25       Impact factor: 4.850

Review 10.  Protein phosphatases in chromatin structure and function.

Authors:  Raquel Sales Gil; Paola Vagnarelli
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-07-20       Impact factor: 4.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.